NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
Clinical Trials
26 trialsNCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT03934684 2025-08-06
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03859427 2024-08-13
ARROW2
Amgen
Phase 3 Completed
NCT01677858 2022-09-23
CHAMPION 1
Amgen
Phase 1/2 Completed
NCT02412878 2022-09-23
ARROW
Amgen
Phase 3 Completed
NCT03029234 2022-05-25
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Amgen
Phase 3 Completed
NCT02335983 2020-11-06
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Amgen
Phase 1 Completed
NCT01818752 2019-08-26
CLARION
Amgen
Phase 3 Completed
NCT00884312 2018-05-14
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
Amgen
Phase 2 Completed
NCT01660750 2017-10-18
11-MM-01
Criterium, Inc.
Phase 1 Completed
NCT00511238 2017-08-31
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Amgen
Phase 2 Completed
NCT01987232 2017-08-28
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
Amgen
Phase 1/2 Completed
NCT00531284 2017-08-15
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
Phase 1/2 Completed
NCT01980589 2017-05-30
CHAMPION 2
Amgen
Phase 1 Completed
NCT00150462 2017-05-02
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Amgen
Phase 1 Completed
NCT00530816 2017-05-02
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
Amgen
Phase 2 Completed
NCT00721734 2017-05-02
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Amgen
Phase 2 Completed
NCT01302392 2017-05-02
FOCUS
Amgen
Phase 3 Completed
NCT01949532 2017-05-02
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Amgen
Phase 1 Completed
NCT01949545 2017-05-02
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Amgen
Phase 1 Completed